GlassScriptPhysician profile
Mohsin Chowdhury
NPI 1407267925
$14,519.84
in general payments reported to CMS, 2019-2025
32 companies · $632 in 2025
The $632 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,149 · 2020: $1,414 · 2021: $5,087 · 2022: $4,973 · 2024: $1,264 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,152 · Travel and Lodging: $744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,152.30 |
| Travel and Lodging | $744.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $3,000.00 | 2021 | |
| Medtronic, INC. | $2,569.45 | 2022 | |
| Philips North America LLC | $2,124.42 | 2020-2025 | (Cm9) Amb Mon & Diag Und, Extended Holter, (Ck6) Holter |
| Boston Scientific Corporation | $1,760.00 | 2019-2024 | Varithena Administration Pack |
| Edwards Lifesciences Corporation | $1,524.36 | 2021 | |
| Abbott Laboratories | $1,413.91 | 2019-2024 | Perclose Proglide |
| Novartis Pharmaceuticals Corporation | $321.94 | 2021-2025 | |
| Medtronic Vascular, INC. | $224.73 | 2019 | |
| Astellas Pharma US INC | $199.94 | 2020 | |
| Janssen Pharmaceuticals, INC | $183.79 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $145.44 | 2022-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.55 | 2022-2025 | Jardiance |
| Cvrx, INC. | $127.72 | 2022 | |
| Amgen INC. | $121.60 | 2021-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $78.53 | 2022-2024 | Camzyos |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $64.49 | 2022-2025 | |
| Heartflow, INC. | $57.01 | 2019 | |
| Abiomed | $51.80 | 2025 | |
| Esperion Therapeutics, INC. | $47.54 | 2021-2025 | Nexletol |
| Alnylam Pharmaceuticals INC. | $47.20 | 2021-2025 | Amvuttra |
| Baxter Healthcare | $46.51 | 2024-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Cardinal Health 200 LLC | $41.95 | 2019 | |
| Bridgebio Pharma, INC. | $37.42 | 2025 | Attruby |
| Opsens INC. | $32.61 | 2022 | |
| Cook Medical LLC | $27.04 | 2019 | |
| Scpharmaceuticals INC. | $22.34 | 2025 | |
| Sanofi-Aventis U.S. LLC | $22.31 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $20.84 | 2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $20.50 | 2025 | |
| Amarin Pharma, INC. | $18.95 | 2021 | |
| Shockwave Medical, INC | $16.85 | 2025 | |
| Kestra Medical Technology Services, INC. | $13.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohsin Chowdhury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.